Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study
Laryngoscope Investigative Otolaryngology · 2026-12 · 11 (6)
DOI: 10.1002/lio2.70642 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 20.11.2026. Verfasst von Sabrina Zapata und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Prolonged intubation can lead to tracheal stenosis, resulting in significant morbidity and impaired quality of life, and in severe cases, results in requiring tracheostomies or invasive surgery to survive. This subgroup analysis evaluated the safety and efficacy of a semicompliant paclitaxel drug‐coated balloon (DCB) in tracheostomy patients with tracheal stenosis.
Methods
This is a subgroup analysis from a prospective, multicenter, single‐arm, open‐label study. Patients received debulking, either laser or coblation, prior to DCB dilation.
Results
Seventeen participants with tracheostomies and tracheal stenoses at baseline were treated at three sites. Etiology was postintubation trauma for 94.1% (16/17) and infectious for one participant. There were four total occlusions (Myer‐Cotton Grade 4) and 11 Grade 3 stenoses. The average stenosis length was 1.68 cm. Freedom from major adverse events at 1 month was 100% (17/17), with 1 procedure‐related serious adverse event (SAE). Successful decannulation rate was 100% within 12 months posttreatment. Kaplan–Meier freedom from target lesion reintervention (TLR) was 70.6% at 6 months and 64.7% at 12 months. SF‐12 physical component scores were significantly improved ( p < 0.05). No patients required open surgery by 12 months.
Conclusion
Paclitaxel DCB appears to be safe to use in the airway. At 12 months, tracheostomy participants experienced low rates of TLR, improved quality of life, no device‐related SAEs, and a high tracheostomy closure rate without the need for invasive surgery. The local antiproliferative effects of the paclitaxel DCB show promise in preventing reinterventions and may provide an option for inoperable patients or postsurgical restenosis treatment. Level of Evidence 4
Zitieren
APA
Zapata, S., Tchkonia, D., Santos, A., O'Malley, E. M., & Vega, F. (2026). Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study. Laryngoscope Investigative Otolaryngology, 11(6). https://doi.org/10.1002/lio2.70642
Vancouver
Zapata S, Tchkonia D, Santos A, O'Malley EM, Vega F. Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study. Laryngoscope Investigative Otolaryngology. 2026;11(6). doi:10.1002/lio2.70642
BibTeX
@article{Zapata2026,
author = {Zapata, Sabrina and Tchkonia, David and Santos, Angelica and O'Malley, Ellen M. and Vega, Fabio},
title = {Paclitaxel‐Coated Balloon Dilation for Tracheal Stenosis in Tracheostomy Patients: 12‐Month Outcomes From a Prospective, Multicenter, Feasibility Study},
journal = {Laryngoscope Investigative Otolaryngology},
year = {2026},
volume = {11},
number = {6},
doi = {10.1002/lio2.70642}
}
EUVIMED